Regado Biosciences (RGDO) IPO Opens 25% Higher

August 22, 2013 10:40 AM EDT Send to a Friend
Get Alerts RGDO Hot Sheet
Trade RGDO Now!
Join SI Premium – FREE
Regado Biosciences (NASDAQ: RGDO) opened for trading at $5 after pricing 10,750,000 shares of its common stock at a price to the public of $4.00 per share, below the expected $5.00 price.

Cowen and Company, LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. Canaccord Genuity Inc., Needham & Company, LLC, and Wedbush PacGrow Life Sciences are acting as co-managers.

Regado Biosciences, Inc. is a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Regado is pioneering the discovery and development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is an actively controllable anticoagulant targeting coagulation Factor IXa for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. The actively controllable product candidates have the potential to improve outcomes, enhance the patient experience and reduce overall treatment costs.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

IPOs

Related Entities

Needham & Company, BMO Capital, Cowen & Co, Canaccord Genuity

Add Your Comment